Herbst Roy S, O'Reilly Michael S
The University of Texas M. D. Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.
Semin Oncol. 2003 Aug;30(4 Suppl 9):113-23. doi: 10.1016/s0093-7754(03)00269-0.
There are a number of novel, biologically targeted therapies, including anti-epidermal growth factor receptor agents (eg, ZD1839 and C225 [cetuximab]), anti-angiogenic agents (eg, vascular endothelial growth factor receptor inhibitors endostatin and angiostatin), and vascular targeting agents (eg, ZD6126), currently undergoing clinical development for a range of human cancers. These agents generally have milder toxicity profiles than conventional cytotoxic agents, and have the potential to be combined effectively with radiotherapy and other conventional modalities in the treatment of malignancies. In this review we consider the mechanistic rationale for combining biologically targeted agents with radiotherapy, present preclinical data to validate this hypothesis, and discuss early clinical investigations of these novel combination therapies, with an emphasis on ongoing trials in non-small cell lung cancer.
目前有多种新型生物靶向疗法正在针对一系列人类癌症进行临床开发，包括抗表皮生长因子受体药物（如ZD1839和C225[西妥昔单抗]）、抗血管生成药物（如血管内皮生长因子受体抑制剂内皮抑素和血管抑素）以及血管靶向药物（如ZD6126）。这些药物的毒性通常比传统细胞毒性药物更轻，并且在恶性肿瘤治疗中有可能与放疗及其他传统治疗方式有效联合。在本综述中，我们探讨了生物靶向药物与放疗联合应用的机制原理，展示临床前数据以验证这一假设，并讨论这些新型联合疗法的早期临床研究，重点关注非小细胞肺癌的正在进行的试验。
